Nymox Pharmaceutical (NASDAQ:NYMX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMXGet Rating) in a report issued on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Shares of NYMX opened at $0.38 on Friday. Nymox Pharmaceutical has a fifty-two week low of $0.35 and a fifty-two week high of $2.27. The business has a 50-day moving average of $1.27 and a 200 day moving average of $1.41. The firm has a market cap of $34.31 million, a P/E ratio of -2.11 and a beta of 1.09.

Nymox Pharmaceutical (NASDAQ:NYMXGet Rating) last issued its earnings results on Wednesday, March 30th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter.

In related news, Director James George Robinson bought 1,151,515 shares of the company’s stock in a transaction on Monday, May 2nd. The shares were purchased at an average price of $1.65 per share, for a total transaction of $1,899,999.75. Following the completion of the transaction, the director now directly owns 4,702,065 shares in the company, valued at approximately $7,758,407.25. The transaction was disclosed in a filing with the SEC, which is available at this link. 54.00% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in NYMX. Millennium Management LLC boosted its position in shares of Nymox Pharmaceutical by 1,834.9% in the second quarter. Millennium Management LLC now owns 323,364 shares of the biopharmaceutical company’s stock valued at $511,000 after acquiring an additional 306,652 shares during the period. Citigroup Inc. bought a new position in Nymox Pharmaceutical in the 1st quarter valued at $137,000. Murchinson Ltd. purchased a new position in shares of Nymox Pharmaceutical during the 1st quarter valued at $96,000. WMS Partners LLC bought a new position in shares of Nymox Pharmaceutical in the first quarter worth $53,000. Finally, MAI Capital Management purchased a new stake in shares of Nymox Pharmaceutical in the first quarter worth $44,000. Hedge funds and other institutional investors own 1.09% of the company’s stock.

About Nymox Pharmaceutical (Get Rating)

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.

Further Reading

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.